IONS logo

Ionis Pharmaceuticals Inc. (IONS)

$28.01

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on IONS

Market cap

$4.66B

EPS

-3.26

P/E ratio

--

Price to sales

8.61

Dividend yield

--

Beta

0.430193

Price on IONS

Previous close

$29.06

Today's open

$29.90

Day's range

$27.97 - $29.99

52 week range

$27.25 - $86.74

Profile about IONS

CEO

Brett P. Monia

Employees

1480

Headquarters

Carlsbad, CA

Exchange

Nasdaq Global Select

Shares outstanding

166545100

Issue type

Common Stock

IONS industries and sectors

Healthcare

Biotechnology & Life Sciences

News on IONS

TRYNGOLZA™ (olezarsen) approved in the EU for severe hypertriglyceridemia (sHTG)

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the European Commission (EC) has approved TRYNGOLZA™ (olezarsen) as an adjunct to diet, in combination with other lipid-lowering therapies, for the treatment of adult patients with severe hypertriglyceridemia (sHTG, fasting triglyceride levels of ≥880 mg/dL [≥10 mmol/L]). TRYNGOLZA is the first and only RNA-targeted therapy authorized in the EU for adults with sHTG ≥880 mg/dL (≥10 mmol/L). The app.

news source

Business Wire • 19 hours ago

news preview

Diranersen demonstrates increasing clinical benefit at two years in early Alzheimer's disease

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared new data from the Phase 2 CELIA study showing increasing clinical benefit of diranersen, an investigational antisense oligonucleotide (ASO) therapy targeting tau, in people living with early Alzheimer's disease at two years (Week 96). Results presented at the Clinical Trials on Alzheimer's Disease (CTAD) 2026 conference showed slowing of clinical decline across measures.

news source

Business Wire • 6 hours ago

news preview

Ionis Pharmaceuticals Sticks to $3 Billion TRYNGOLZA Sales Goal Despite Slow Start

Ionis Pharmaceuticals NASDAQ: IONS remains confident that its triglyceride-lowering drug TRYNGOLZA can generate more than $3 billion in peak annual U.S. sales, even as its launch has started more slowly than expected, CEO Brett Monia said at the UBS Global Biopharma Conference.

news source

MarketBeat • Nov 16, 2026

news preview

Ionis Pharmaceuticals, Inc. (IONS) Securities Investigation Notice - Levi & Korsinsky

TRYNGOLZA sales fell to $9.3 million from $31.8 million a year earlier, and IONS shares dropped on the product-level numbers. Levi & Korsinsky is investigating potential securities law violations on behalf of shareholders who lost money.

news source

PRNewsWire • Nov 16, 2026

news preview

Ionis Pharmaceuticals, Inc. (IONS) Presents at UBS Global Biopharma Conference 2026 Transcript

Ionis Pharmaceuticals, Inc. ( IONS ) UBS Global Biopharma Conference 2026 November 16, 2026 5:00 AM EST Company Participants Brett Monia - Founder, CEO & Director Conference Call Participants Joon Lee - UBS Investment Bank, Research Division Presentation Joon Lee UBS Investment Bank, Research Division All right. We'll get started.

news source

Seeking Alpha • Nov 16, 2026

news preview

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Ionis Pharmaceuticals, Inc. (IONS)

Ionis cut its full-year TRYNGOLZA sales outlook by roughly half as third-quarter sales of the drug only achieved $9.3 million; IONS investors who lost money may have legal rights as an investigation gets underway Ionis cut its full-year TRYNGOLZA sales outlook by roughly half as third-quarter sales of the drug only achieved $9.3 million; IONS investors who lost money may have legal rights as an investigation gets underway

news source

GlobeNewsWire • Nov 12, 2026

news preview

Wolf Popper LLP Announces Investigation on Behalf of Ionis Pharmaceuticals, Inc. Investors

NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of purchasers of Ionis Pharmaceuticals, Inc. (Ionis) common stock (NASDAQ: IONS).

news source

GlobeNewsWire • Nov 12, 2026

news preview

Ionis presents new long-term data supporting durable efficacy and disease control with DAWNZERA® (donidalorsen) at ACAAI 2026 Annual Meeting

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced new long-term data for DAWNZERA® (donidalorsen), the first and only RNA-targeted medicine for hereditary angioedema (HAE), to be presented at the 2026 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Phoenix, Arizona. Multiple presentations will demonstrate the long-term efficacy and safety of DAWNZERA in the OASISplus open-label extension (OLE) and switch cohort.

news source

Business Wire • Nov 12, 2026

news preview

Here's Why Ionis Pharmaceuticals' Stock is Down 28.5% Post Q3 Earnings

IONS plunges as slower Tryngolza sales, reduced guidance and disappointing Wainua royalties rattle investors.

news source

Zacks Investment Research • Nov 11, 2026

news preview

AMG TimesSquare Mid Cap Growth Fund Q3 2026 Portfolio Update

During this quarter, AMG TimesSquare Mid Cap Growth Fund performed in line with the Russell Midcap® Growth Index. Our leading contributors were software and health care technology companies that exceeded expectations for the fiscal quarter, with each pointing to AI as an expanding source of demand. Our overweight in Industrials, one of the benchmark's weakest sectors, also weighed on allocation.

news source

Seeking Alpha • Nov 11, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Ionis Pharmaceuticals Inc.

Open an M1 investment account to buy and sell Ionis Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in IONS on M1